Cathie Wood, the CEO of Ark Investment, has made a name for herself by betting on cutting-edge technology with financial technology stocks, or fintechs, and biotechnology growth stocks making up a significant part of her exchange-traded funds (ETFs). While many growth stocks fell out of favor the past two years, her flagship ARK Innovation ETF (NYSEMKT: ARKK) is up more than 44% so far this year.

Two of the Wood investments that I believe will deliver long-term superior returns are gene-editing biotechs, Intellia Therapeutics (NASDAQ: NTLA) and CRISPR Therapeutics (NASDAQ: CRSP), while another is the fintech Block (NYSE: SQ). All three companies are well off their 52-week highs, but have seen their shares rise so far this year.

Here's why each of these stocks could deliver elite returns.

Continue reading

Source Fool.com